Timing of PSA response to guide cessation of docetaxel in prostate cancer.

被引：0
|
作者：
Dickinson, Peter D.
Malik, Jahangeer
Slevin, Finbar
Sivanandan, Ananth
Clarke, Noel W.
Choudhury, Ananya
Elliott, Tony
机构：
[1] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[2] NHS Lothian, Western Gen Hosp, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16069
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Detection of circulating prostatic cells by PSA RT-PCR in prostate cancer.
    de la Taille, A
    Salomon, L
    Colombel, M
    Abbou, CC
    Chopin, D
    Groux-Muscatelli, B
    PROGRES EN UROLOGIE, 1999, 9 (06): : 1084 - 1089
  • [42] Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer.
    Smith, MR
    Kabbinavar, F
    Saad, F
    Hussain, A
    Hei, YJ
    Small, E
    Cook, R
    Higano, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 381S - 381S
  • [43] Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.
    Bikkasani, Krishna
    Qin, Qian
    Lin, Justin
    Galsky, Matt D.
    Liaw, Bobby Chi-Hung
    Oh, William K.
    Tsao, Che-Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [44] The relative velocity of serum PSA predicts prognosis in hormone refractory prostate cancer.
    Vollmer, RT
    Kantoff, PW
    Dawson, NA
    Vogelzang, NJ
    LABORATORY INVESTIGATION, 1999, 79 (01) : 109A - 109A
  • [45] Impact of statin therapy on PSA kinetics during active surveillance of prostate cancer.
    Rogers, William
    Rothschild, Daniel
    Bylund, Jason R.
    Venkatesh, Ramakrishna
    Demos, Jon
    Strup, Stephen E.
    Preston, David
    Crispen, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [46] Prognostic significance of PSA in the outcomes of patients with high risk localized prostate cancer.
    Khosla, Atulya Aman
    Prabhakar, Pushan
    Pon Avudaiappan, Arjun
    Jatwani, Karan
    Ahluwalia, Manmeet Singh
    Manoharan, Murugesan
    Garje, Rohan
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 347 - 347
  • [47] Effect of obesity on PSA density (PSAD): A new clinical predictor of prostate cancer.
    Garzotto, M.
    Mongoue-Tchokote, S.
    Shannon, J.
    Peters, L.
    Sokoloff, M. H.
    Beer, T. M.
    Mori, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 245S - 245S
  • [48] Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel
    Ahmet Taner Sümbül
    Ahmet Sezer
    Hüseyin Abalı
    Fatih Köse
    İlhami Gültepe
    Hüseyin Mertsoylu
    Sadık Muallaoğlu
    Özgür Özyılkan
    International Urology and Nephrology, 2014, 46 : 1531 - 1535
  • [49] Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel
    Sumbul, Ahmet Taner
    Sezer, Ahmet
    Abali, Huseyin
    Kose, Fatih
    Gultepe, Ilhami
    Mertsoylu, Huseyin
    Muallaoglu, Sadik
    Ozyilkan, Ozgur
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (08) : 1531 - 1535
  • [50] Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.
    Bukhari, Nedal
    Potvin, Kvica R.
    Ernst, D. Scott
    Sax, Lori
    Winquist, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345